Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab.
Respir Med Case Rep
; 28: 100899, 2019.
Article
in En
| MEDLINE
| ID: mdl-31341763
ABSTRACT
We described three severe asthmatics whose asthma symptoms were rapidly improved by benralizumab following favorable response to mepolizumab. Benralizumab-induced eosinophil depletion contributed to clinical improvement of severe asthma after mepolizumab-induced eosinophil reduction; thus, prior favorable responses to mepolizumab may predict benralizumab efficacy.
ACT, Asthma control test; BT, bronchial thermoplasty; Benralizumab; CT, computed tomography; Eosinophil; FEV1, expiratory volume in 1 second; FVC, forced vital capacity; FeNO, fraction of exhaled nitric oxide; ICS, inhaled corticosteroids; LABA, long-acting beta-agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene antagonist; Mepolizumab; Severe asthma
Full text:
1
Database:
MEDLINE
Therapeutic Methods and Therapies TCIM:
Terapias_biologicas
/
Peloideterapia
Type of study:
Prognostic_studies
Language:
En
Journal:
Respir Med Case Rep
Year:
2019
Type:
Article
Affiliation country:
Japan